1. Home
  2. PARK vs NEPH Comparison

PARK vs NEPH Comparison

Compare PARK & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PARK

Park Dental Partners Inc.

N/A

Current Price

$15.50

Market Cap

67.5M

Sector

Health Care

ML Signal

N/A

Logo Nephros Inc.

NEPH

Nephros Inc.

HOLD

Current Price

$4.95

Market Cap

60.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PARK
NEPH
Founded
1972
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Misc Health and Biotechnology Services
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
67.5M
60.0M
IPO Year
2025
2004

Fundamental Metrics

Financial Performance
Metric
PARK
NEPH
Price
$15.50
$4.95
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
95.5K
58.2K
Earning Date
02-08-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
3.18
N/A
EPS
2.91
0.14
Revenue
$240,209,000.00
$17,930,000.00
Revenue This Year
N/A
$33.32
Revenue Next Year
N/A
$12.27
P/E Ratio
$5.05
$35.51
Revenue Growth
7.47
32.36
52 Week Low
$9.53
$1.39
52 Week High
$17.84
$6.42

Technical Indicators

Market Signals
Indicator
PARK
NEPH
Relative Strength Index (RSI) N/A 47.71
Support Level N/A $4.65
Resistance Level N/A $5.24
Average True Range (ATR) 0.00 0.32
MACD 0.00 -0.02
Stochastic Oscillator 0.00 33.94

Price Performance

Historical Comparison
PARK
NEPH

About NEPH Nephros Inc.

Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.

Share on Social Networks: